Arcturus Therapeutics is trading at $13.86, down -5.46%, with no confirmed company-specific announcement or event surfaced in the search to explain the October 6 decline.
- Recent company coverage highlighted earlier clinical data and an analyst rating change.
- Broader market indices are reported higher, while the supplied sector note cites biotech weakness; available XBI data conflict with that account, leaving the specific driver unclear.